Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress scales back inpatient reductions

This article was originally published in The Gray Sheet

Executive Summary

Congress moves to reduce offsets to Medicare hospital inpatient payments during the week of Sept. 24, just before the cuts are slated to go into effect Oct. 1. Under CMS' fiscal 2008 inpatient rule, payments would be reduced across-the-board by 1.2% in 2008, and by 1.8% in both 2009 and 2010 to maintain budget neutrality amidst expected changes in coding practice due to a switch to new severity-based payment classifications (1"The Gray Sheet" Aug. 6, 2007, p. 6). The House and Senate passed legislation (H.R. 3668) Sept. 26 and 27, respectively, that shrinks the offsets to 0.6% in 2008 and 0.9% in 2009. The adjustment for 2010 is still on the table. The American Hospital Association says it will continue to lobby to further mitigate reductions

You may also be interested in...

CMS Inpatient Makeover Continues In 2008 With Stable Device Payments

Medicare payments for hospital inpatient procedures with high-tech medical devices will remain mostly stable in fiscal year 2008, the final rule issued Aug. 1 by CMS suggests

Pandemic-Related Price-Gouging Would Be False, Misleading Advertising Under House, Senate Bills

House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.

COVID-19 Trial Changes Are “Propulsive Force” For Digital Adoption

Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts